The Motley Fool

GlaxoSmithKline Plc: The Cheap Remedy For Market Upsets

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Recent turbulence in the markets is a reminder of the benefits of having a core holding of defensive shares. But dire interest rates and fear of a bond bear market have spurred investors to switch from cash and bonds into quality defensive shares, many of which pay handsome yields and offer bond-like security.

The result? Stocks like Unilever and Diageo are trading at historically high multiples, with prospective price-to-earnings (P/E) multiples of 19.7 and 19.4 respectively. It’s no cause to panic — both these stocks have great brands and diversified earnings. Investors may sacrifice potential upside if there’s a stock market rally but they’re getting good downside protection in return, while picking up a decent yield.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Cheapest

But for my money, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) stands out as the cheapest of the quality defensive stocks. It’s on a prospective P/E of 15, not far above the market average, and yields 4.5%.

I’m not alone in being a fan of GSK. Deutsche Bank upgraded the shares to a ‘buy’ last month and said they should trade at 1,930p to be on a par with peers whose shares have recovered better since earnings were downgraded in the sector in 2011. That helped push GSK’s shares to an 11-year high, but at 1,742p today they’re still well below Deutsche’s target price.

Barclays upgraded GSK in January. The indication from both brokers is that the company has turned the corner on its patent cliff, the issue that has dogged pharmaceutical companies in recent years. The impact of drugs coming off patent has mostly run its course with GSK and new products are in the offing, including melanoma, HIV and lung disease therapies.

Diversification

What’s more, GSK successfully diversified away from a pure pharma business model some years ago. 30% of sales come from vaccines, which have a lower-risk profile, and consumer healthcare, with products such as Lucozade, Sensodyne and Panadol.

It has also pushed hard into emerging markets where growing and ageing middle classes are driving increased drugs sales, though recent developments in China highlight the dangers inherent in such countries. China’s anti-trust watchdog is expected to force down prices, while some GSK employees have been accused of ‘economic crimes’.

GSK has another fan, too. One of its biggest shareholders is Invesco Perpetual’s star fund manager Neil Woodford. Mr Woodford’s high income fund is “the best performing of any fund investing in the UK since it launched”, according to Hargreaves Lansdown. Nearly a quarter of his £22bn funds are invested in just three companies in the pharmaceutical sector, including GSK.

You can learn more about how Mr Woodford selects stocks, and the identity of his other pharmaceutical investments, in an exclusive report from the Motley Fool. You can download it by clicking here — it’s free.

> Tony owns shares in GSK, Unilever and Diageo but no other shares mentioned in this article. The Motley Fool has recommended shares in Unilever.

One Killer Stock For The Cybersecurity Surge

Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028more than double what it is today!

And with that kind of growth, this North American company stands to be the biggest winner.

Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…

We think it has the potential to become the next famous tech success story.

In fact, we think it could become as big… or even BIGGER than Shopify.

Click here to see how you can uncover the name of this North American stock that’s taking over Silicon Valley, one device at a time…

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.